

CLAIMS

1. A polypeptide, a composition comprising the polypeptide, or a composition comprising a nucleic acid comprising a nucleotide sequence that encodes the polypeptide, for use as a medicament, wherein the polypeptide comprises or consists of at least one immunoglobulin single variable domain (ISVD) that specifically binds to IL-13 or TSLP, wherein said ISVD comprises three complementarity determining regions (CDR1 to CDR3, respectively), and wherein the at least one ISVD comprises:
- 5
- 10 a) a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
- a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
- 15 a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17,
- 20 b) a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
- a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
- 25 a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,

- 5 c) a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
- a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, or
- 10 d) a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
- a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
- 15 a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21.

2. The polypeptide or composition for use according to claim 1, wherein the at least one ISVD that specifically binds to IL-13 or TSLP comprises:

20

- a) a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,
- b) a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,
- 25

- c) a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, or
- d) a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.
3. The polypeptide or composition for use according to any of claims 1 or 2, wherein the amino acid sequence of the at least one ISVD that specifically binds to IL-13 or TSLP comprises:
- a) a sequence identity of more than 90% with SEQ ID NO: 2,
- b) a sequence identity of more than 90% with SEQ ID NO: 3,
- c) a sequence identity of more than 90% identity with SEQ ID NO: 4, or
- d) a sequence identity of more than 90% identity with SEQ ID NO: 6.
4. The polypeptide or composition for use according to any of claims 1 to 3, wherein said at least one ISVD that specifically binds to IL-13 or TSLP comprises:
- a) the amino acid sequence of SEQ ID NO: 2,
- b) the amino acid sequence of SEQ ID NO: 3,
- c) the amino acid sequence of SEQ ID NO: 4, or
- d) the amino acid sequence of SEQ ID NO: 6.
5. The polypeptide or composition for use according to claim 1, wherein the polypeptide comprises or consists of at least two ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least two ISVDs are optionally linked via one or more peptidic linkers, and wherein:
- a) a first and a second ISVD specifically binds to IL-13 and comprises

- 5
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17,
- 10 b) a first and a second ISVD specifically binds to IL-13 and comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
 - 15 ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,
- 20 c) a first ISVD specifically binds to IL-13 and comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - 25 ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17, and

a second ISVD specifically binds to IL-13 and comprises

- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
- 5 v. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
- vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,
- 10

d) a first ISVD specifically binds to IL-13 and comprises

- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
- 15 ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
- iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18, and
- 20

a second ISVD specifically binds to IL-13 and comprises

- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
- 25 v. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and

- vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with has 2 or 1 amino acid difference(s) with SEQ ID NO: 17,

e) a first ISVD specifically binds to TSLP and comprises

- 5 i. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
- 10 iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21, and

a second ISVD specifically binds to TSLP and comprises

- 15 iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- 20 vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, or

f) a first ISVD specifically binds to TSLP and comprises

- 25 i. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;

- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, and

a second ISVD specifically binds to TSLP and comprises

- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
- vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

6. The polypeptide or composition for use according to claim 5, wherein:

- a) the first and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,
- b) the first and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,
- c) the first ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17, and the second ISVD

that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,

5 d) the first ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18, and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,

10 e) the first ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21, and the second ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, or

15 f) the first ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, and the second ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.

7. The polypeptide or composition for use according to any of claims 5 or 6, wherein:

- 25 a) the amino acid sequence of the first and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 2,
- b) the amino acid sequence of the first and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 3,

- c) the amino acid sequence of the first ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 2, and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% identity with SEQ ID NO: 3,
- 5 d) the amino acid sequence of the first ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 3, and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% identity with SEQ ID NO: 2,
- e) the amino acid sequence of the first ISVD that specifically binds to TSLP comprises
10 a sequence identity of more than 90% with SEQ ID NO: 6, and the second ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% identity with SEQ ID NO: 4,
- f) the amino acid sequence of the first ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% with SEQ ID NO: 4, and the second ISVD that
15 specifically binds to TSLP comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.
8. The polypeptide or composition for use according to any of claims 5 to 7, wherein:
- a) the first and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2,
- 20 b) the first and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3,
- c) the first ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2, and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3,
- 25 d) the first ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3, and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2,

- e) the first ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 6, and the second ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 4, or
- f) the first ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 4, and the second ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 6.

9. The polypeptide according to any of claims 5 to 8, wherein the polypeptide comprises or consists of:

- a) the amino acid sequence of SEQ ID NO: 148,
- b) the amino acid sequence of SEQ ID NO: 149,
- c) the amino acid sequence of SEQ ID NO: 150,
- d) the amino acid sequence of SEQ ID NO: 151,
- e) the amino acid sequence of SEQ ID NO: 152,
- f) the amino acid sequence of SEQ ID NO: 153,
- g) the amino acid sequence of SEQ ID NO: 154,
- h) the amino acid sequence of SEQ ID NO: 155,
- i) the amino acid sequence of SEQ ID NO: 156,
- j) the amino acid sequence of SEQ ID NO: 157,
- k) the amino acid sequence of SEQ ID NO: 158, or
- l) the amino acid sequence of SEQ ID NO: 159.

10. The polypeptide or composition for use according to any of claims 1 or 5, wherein the polypeptide comprises or consists of at least four ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptidic linkers, and wherein:

- a) a first ISVD specifically binds to IL-13 and comprises

- 5
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17;
- 10 b) a second ISVD specifically binds to IL-13 and comprises
- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
 - 15 v. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
 - vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18;
- 20 c) a third ISVD specifically binds to TSLP and comprises
- vii. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
 - 25 viii. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
 - ix. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19; and

d) a fourth ISVD specifically binds to TSLP and comprises

x. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;

5 xi. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and

10 xii. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

11. The composition for use according to any one of claims 1 to 10, which is a pharmaceutical composition which further comprises at least one
15 pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further pharmaceutically active polypeptides and/or compounds.

12. The polypeptide or composition for use according to claim 10 or 11, wherein:

20 a) said first ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17;

b) said second ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18;

25 c) said third ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19; and

d) said fourth ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.

13. The polypeptide or composition for use according to any of claims 10 to 12,
5 wherein:

a) the amino acid sequence of said first ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 2;

b) the amino acid sequence of said second ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 3;

10 c) the amino acid sequence of said third ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 4; and

d) the amino acid sequence of said fourth ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.

14. The polypeptide or composition for use according to any of claims 10 to 13,
15 wherein:

a) said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;

b) said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;

c) said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and

d) said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.

20 15. The polypeptide or composition for use according to any of claims 1 to 14,
wherein said polypeptide further comprises one or more other groups, residues,
moieties or binding units, optionally linked via one or more peptidic linkers, in which
said one or more other groups, residues, moieties or binding units provide the
polypeptide with increased half-life, compared to the corresponding polypeptide
25 without said one or more other groups, residues, moieties or binding units.

16. The polypeptide or composition for use according to claim 15, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of a polyethylene glycol molecule, serum proteins or fragments thereof, binding units that can bind to serum proteins, an Fc portion, and small proteins or peptides that can bind to serum proteins.
17. The polypeptide or composition for use according to any one of claims 15 to 16, in which said one or more other binding units that provide the polypeptide with increased half-life is chosen from the group consisting of binding units that can bind to serum albumin (such as human serum albumin) or a serum immunoglobulin (such as IgG).
18. The polypeptide or composition for use according to claim 17, in which said binding unit that provides the polypeptide with increased half-life is an ISVD that can bind to human serum albumin.
19. The polypeptide or composition for use according to claim 18, wherein the ISVD binding to human serum albumin comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 10;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 15 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 15; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 20.
20. The polypeptide or composition for use according to any of claims 18 to 19, wherein the ISVD binding to human serum albumin comprises a CDR1 that is the amino

acid sequence of SEQ ID NO: 10, a CDR2 that is the amino acid sequence of SEQ ID NO: 15 and a CDR3 that is the amino acid sequence of SEQ ID NO: 20.

21. The polypeptide or composition for use according to any of claims 18 to 20, wherein the amino acid sequence of said ISVD binding to human serum albumin comprises a sequence identity of more than 90% with SEQ ID NO: 5.
22. The polypeptide or composition for use according to any of claims 18 to 21, wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.
23. The polypeptide or composition for use according to any of claims 10 to 22, wherein the amino acid sequence of the polypeptide comprises a sequence identity of more than 90% with SEQ ID NO: 1.
24. The polypeptide or composition for use according to any of claims 10 to 23, wherein the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1.
25. The polypeptide or composition for use according to any of claims 1 to 24, for use in the treatment of an inflammatory disease, such as a type 2 inflammatory disease.
26. The polypeptide or composition for use according to claim 25, wherein the type 2 inflammatory disease is selected from asthma and atopic dermatitis.
27. A polypeptide that comprises or consists of at least one immunoglobulin single variable domain (ISVD) that specifically binds to IL13 or TSLP, wherein said ISVD comprises three complementarity determining regions (CDR1 to CDR3, respectively); and wherein the at least one ISVD comprises:
- a) a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;

a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and

5

a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17,

b) a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;

10

a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and

15

a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,

c) a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;

20

a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and

a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, or

25

d) a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;

a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and

5 a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21.

28. The polypeptide according to claim 27, wherein the at least one ISVD that specifically binds to IL-13 or TSLP comprises:

10 a) a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,

b) a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,

15 c) a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, or

d) a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.

29. The polypeptide according to any of claims 27 or 28, wherein the amino acid sequence of the at least one ISVD that specifically binds to IL-13 or TSLP comprises:

a) a sequence identity of more than 90% with SEQ ID NO: 2,

b) a sequence identity of more than 90% with SEQ ID NO: 3,

25 c) a sequence identity of more than 90% identity with SEQ ID NO: 4, or

d) a sequence identity of more than 90% identity with SEQ ID NO: 6.

30. The polypeptide according to any of claims 27 to 29, wherein said at least one ISVD that specifically binds to IL-13 or TSLP comprises:

- a) the amino acid sequence of SEQ ID NO: 2,
- b) the amino acid sequence of SEQ ID NO: 3,
- 5 c) the amino acid sequence of SEQ ID NO: 4, or
- d) the amino acid sequence of SEQ ID NO: 6.

31. The polypeptide according to claim 27, wherein the polypeptide comprises or consists of at least two ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least two ISVDs are
10 optionally linked via one or more peptidic linkers, and wherein:

- a) a first and a second ISVD specifically binds to IL-13 and comprises
 - i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - 15 ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17,
 - 20
- b) a first and a second ISVD specifically binds to IL-13 and comprises
 - i. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
 - 25 ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and

- iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,

c) a first ISVD specifically binds to IL-13 and comprises

- 5 i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
- 10 iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17, and

a second ISVD specifically binds to IL-13 and comprises

- 15 iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
- 20 vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18,

d) a first ISVD specifically binds to IL-13 and comprises

- 25 i. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;

- 5
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18, and

a second ISVD specifically binds to IL-13 and comprises

- 10
- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - v. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - 15 vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17,

e) a first ISVD specifically binds to TSLP and comprises

- 20
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
 - 25 iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21, and

a second ISVD specifically binds to TSLP and comprises

- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, or
- f) a first ISVD specifically binds to TSLP and comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
- ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19, and
- a second ISVD specifically binds to TSLP and comprises
- iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
- v. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
- vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21,

wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.

32. The polypeptide according to claim 31, wherein:

- 5 a) the first and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,
- b) the first and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18,
- 10 c) the first ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17, and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3
15 that is the amino acid sequence of SEQ ID NO: 18,
- d) the first ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18, and the second ISVD that specifically binds to IL-13 comprises a CDR1 that is the amino acid sequence of
20 SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17,
- e) the first ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21, and the second ISVD
25 that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, or

f) the first ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19, and the second ISVD that specifically binds to TSLP comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.

33. The polypeptide according to any of claims 31 or 32, wherein:

- a) the amino acid sequence of the first and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 2,
- 10 b) the amino acid sequence of the first and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 3,
- c) the amino acid sequence of the first ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 2, and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% identity with SEQ ID NO: 3,
- 15 d) the amino acid sequence of the first ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% with SEQ ID NO: 3, and the second ISVD that specifically binds to IL-13 comprises a sequence identity of more than 90% identity with SEQ ID NO: 2,
- 20 e) the amino acid sequence of the first ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% with SEQ ID NO: 6, and the second ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% identity with SEQ ID NO: 4,
- 25 f) the amino acid sequence of the first ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% with SEQ ID NO: 4, and the second ISVD that specifically binds to TSLP comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.

34. The polypeptide according to any of claims 31 to 33, wherein:

- a) the first and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2,
- b) the first and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3,
- c) the first ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2, and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3,
- d) the first ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 3, and the second ISVD that specifically binds to IL-13 comprises the amino acid sequence of SEQ ID NO: 2,
- e) the first ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 6, and the second ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 4, or
- f) the first ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 4, and the second ISVD that specifically binds to TSLP comprises the amino acid sequence of SEQ ID NO: 6.

35. The polypeptide according to any of claims 31 to 34, wherein the polypeptide comprises or consists of:

- a) the amino acid sequence of SEQ ID NO: 148,
- b) the amino acid sequence of SEQ ID NO: 149,
- c) the amino acid sequence of SEQ ID NO: 150,
- d) the amino acid sequence of SEQ ID NO: 151,
- e) the amino acid sequence of SEQ ID NO: 152,
- f) the amino acid sequence of SEQ ID NO: 153,
- g) the amino acid sequence of SEQ ID NO: 154,
- h) the amino acid sequence of SEQ ID NO: 155,
- i) the amino acid sequence of SEQ ID NO: 156,
- j) the amino acid sequence of SEQ ID NO: 157,

- k) the amino acid sequence of SEQ ID NO: 158, or
- l) the amino acid sequence of SEQ ID NO: 159.

36. The polypeptide according to any of claims 27 or 31, wherein the polypeptide comprises or consists of at least four ISVDs, wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), wherein the at least four ISVDs are optionally linked via one or more peptidic linkers, and wherein:

- a) a first ISVD specifically binds to IL-13 and comprises
 - i. a CDR1 that is the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 7;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 17 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 17;
- b) a second ISVD specifically binds to IL-13 and comprises
 - iv. a CDR1 that is the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 8;
 - v. a CDR2 that is the amino acid sequence of SEQ ID NO: 13 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and
 - vi. a CDR3 that is the amino acid sequence of SEQ ID NO: 18 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 18;
- c) a third ISVD specifically binds to TSLP and comprises

- vii. a CDR1 that is the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 9;
- viii. a CDR2 that is the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 14; and
- ix. a CDR3 that is the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 19; and
- d) a fourth ISVD specifically binds to TSLP and comprises
- x. a CDR1 that is the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 11;
- xi. a CDR2 that is the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 16; and
- xii. a CDR3 that is the amino acid sequence of SEQ ID NO: 21 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 21,
- wherein the order of the ISVDs indicates their relative position to each other considered from the N-terminus to the C-terminus of said polypeptide.
37. The polypeptide according to claim 36, wherein:
- a) said first ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 7, a CDR2 that is the amino acid sequence of SEQ ID NO: 12 and a CDR3 that is the amino acid sequence of SEQ ID NO: 17;
- b) said second ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 8, a CDR2 that is the amino acid sequence of SEQ ID NO: 13 and a CDR3 that is the amino acid sequence of SEQ ID NO: 18;

- c) said third ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 9, a CDR2 that is the amino acid sequence of SEQ ID NO: 14 and a CDR3 that is the amino acid sequence of SEQ ID NO: 19; and
- d) said fourth ISVD comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 11, a CDR2 that is the amino acid sequence of SEQ ID NO: 16 and a CDR3 that is the amino acid sequence of SEQ ID NO: 21.
38. The polypeptide according to any of claims 36 or 37, wherein:
- a) the amino acid sequence of said first ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 2;
- b) the amino acid sequence of said second ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 3;
- c) the amino acid sequence of said third ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 4; and
- d) the amino acid sequence of said fourth ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.
39. The polypeptide according to any of claims 36 to 38, wherein:
- a) said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;
- b) said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;
- c) said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and
- d) said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.
40. The polypeptide according to any of claims 27 to 39, wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said one or more other groups, residues, moieties or binding units provide the polypeptide with increased

half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.

41. The polypeptide according to claim 40, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of a polyethylene glycol molecule, serum proteins or fragments thereof, binding units that can bind to serum proteins, an Fc portion, and small proteins or peptides that can bind to serum proteins.
42. The polypeptide according to any one of claims 40 to 41, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of binding units that can bind to serum albumin (such as human serum albumin) or a serum immunoglobulin (such as IgG).
43. The polypeptide according to claim 42, in which said binding unit that provides the polypeptide with increased half-life is an ISVD that can bind to human serum albumin.
44. The polypeptide according to claim 43, wherein the ISVD binding to human serum albumin comprises
- i. a CDR1 that is the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 10;
 - ii. a CDR2 that is the amino acid sequence of SEQ ID NO: 15 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 15; and
 - iii. a CDR3 that is the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence with 2 or 1 amino acid difference(s) with SEQ ID NO: 20.

45. The polypeptide according to any of claims 43 to 44, wherein the ISVD binding to human serum albumin comprises a CDR1 that is the amino acid sequence of SEQ ID NO: 10, a CDR2 that is the amino acid sequence of SEQ ID NO: 15 and a CDR3 that is the amino acid sequence of SEQ ID NO: 20.
- 5 46. The polypeptide according to any of claims 43 to 45, wherein the amino acid sequence of said ISVD binding to human serum albumin comprises a sequence identity of more than 90% with SEQ ID NO: 5.
47. The polypeptide according to any of claims 43 to 46, wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.
- 10 48. The polypeptide according to any of claims 36 to 47, wherein the amino acid sequence of the polypeptide comprises a sequence identity of more than 90% with SEQ ID NO: 1.
49. The polypeptide according to any of claims 36 to 48, wherein the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1.
- 15 50. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide according to any of claims 27 to 49, or a polypeptide according to claims 36 to 49.
51. A host or host cell comprising a nucleic acid according to claim 50.
52. A method for producing a polypeptide according to any of claims 27 to 49, or a polypeptide according to claims 36 to 49, said method at least comprising the steps of:
- 20 a) expressing, in a suitable host cell or host organism or in another suitable expression system, a nucleic acid according to claim 50; optionally followed by:
- b) isolating and/or purifying the polypeptide according to any of claims 27 to 49, or the polypeptide according to claims 36 to 49.

53. A composition comprising at least one polypeptide according to any of claims 27 to 49, or at least one polypeptide according to claims 36 to 49, or a nucleic acid according to claim 50.
54. The composition according to claim 53, which is a pharmaceutical composition
5 which further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further pharmaceutically active polypeptides and/or compounds.
55. A method of treating an inflammatory disease, preferably a type 2 inflammatory
10 disease, wherein said method comprises administering, to a subject in need thereof, a pharmaceutically active amount of a polypeptide according to any of claims 27 to 49, or according to claims 36 to 49, or a composition according to any of claims 53 to 54.
56. The method according to claim 55, wherein the type 2 inflammatory disease is selected from asthma and atopic dermatitis.
57. Use of a polypeptide according to any of claims 27 to 49, preferably according to
15 claims 36 to 49, or a composition according to any of claims 53 to 54, in the preparation of a pharmaceutical composition for treating an inflammatory disease, such as a type 2 inflammatory disease.
58. Use of the polypeptide or a composition according to claims 57, wherein the type 2 inflammatory disease is selected from asthma and atopic dermatitis.